Page last updated: 2024-09-03

3-n-methylspiperone and Basal Ganglia Diseases

3-n-methylspiperone has been researched along with Basal Ganglia Diseases in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Eriksson, B; Farde, L; Halldin, C; Nyberg, S; Oxenstierna, G	1

Trials

1 trial(s) available for 3-n-methylspiperone and Basal Ganglia Diseases

Article	Year
Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. The American journal of psychiatry, 1999, Volume: 156, Issue:6 Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Brain; Carbon Radioisotopes; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorine Radioisotopes; Humans; Male; Psychiatric Status Rating Scales; Raclopride; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Receptors, Serotonin; Risperidone; Salicylamides; Schizophrenia; Schizophrenic Psychology; Spiperone; Tomography, Emission-Computed; Treatment Outcome	1999

Article

Year

The American journal of psychiatry, 1999, Volume: 156, Issue:6

Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Brain; Carbon Radioisotopes; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorine Radioisotopes; Humans; Male; Psychiatric Status Rating Scales; Raclopride; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Receptors, Serotonin; Risperidone; Salicylamides; Schizophrenia; Schizophrenic Psychology; Spiperone; Tomography, Emission-Computed; Treatment Outcome

1999